These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 24917306

  • 1. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
    Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M.
    Cancer; 2014 Oct 01; 120(19):2986-95. PubMed ID: 24917306
    [Abstract] [Full Text] [Related]

  • 2. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
    Sivalingam VN, Kitson S, McVey R, Roberts C, Pemberton P, Gilmour K, Ali S, Renehan AG, Kitchener HC, Crosbie EJ.
    Br J Cancer; 2016 Feb 02; 114(3):281-9. PubMed ID: 26794276
    [Abstract] [Full Text] [Related]

  • 3. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
    Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L, Lu KH.
    Gynecol Oncol; 2016 Dec 02; 143(3):466-471. PubMed ID: 27745917
    [Abstract] [Full Text] [Related]

  • 4. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
    Dong L, Zhou Q, Zhang Z, Zhu Y, Duan T, Feng Y.
    J Obstet Gynaecol Res; 2012 Aug 02; 38(8):1077-85. PubMed ID: 22540333
    [Abstract] [Full Text] [Related]

  • 5. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
    Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H, Nakajima A.
    Mol Carcinog; 2010 Jul 02; 49(7):662-71. PubMed ID: 20564343
    [Abstract] [Full Text] [Related]

  • 6. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
    Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH.
    Gynecol Oncol; 2014 Sep 02; 134(3):607-14. PubMed ID: 24972190
    [Abstract] [Full Text] [Related]

  • 7. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
    Dowling RJ, Niraula S, Chang MC, Done SJ, Ennis M, McCready DR, Leong WL, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V.
    Breast Cancer Res; 2015 Mar 03; 17(1):32. PubMed ID: 25849721
    [Abstract] [Full Text] [Related]

  • 8. Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.
    Bateman NW, Teng PN, Hope E, Hood BL, Oliver J, Ao W, Zhou M, Wang G, Tommarello D, Wilson K, Litzy T, Conrads KA, Hamilton CA, Darcy KM, Casablanca Y, Maxwell GL, Bae-Jump V, Conrads TP.
    Cancer Med; 2020 Feb 03; 9(3):1092-1103. PubMed ID: 31808620
    [Abstract] [Full Text] [Related]

  • 9. [Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
    Bershteĭn LM, Maksimov SIa, Danilova MA, Gershfel'd ÉD, Boiarkina MP, Khadzhimba AS, Kovalevskiĭ AIu, Turkevich EA, Meshkova IE.
    Vopr Onkol; 2011 Feb 03; 57(6):737-41. PubMed ID: 22416390
    [Abstract] [Full Text] [Related]

  • 10. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
    Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A.
    J Clin Oncol; 2012 Jul 20; 30(21):2593-600. PubMed ID: 22564993
    [Abstract] [Full Text] [Related]

  • 11. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
    Li B, Takeda T, Tsuiji K, Kondo A, Kitamura M, Wong TF, Yaegashi N.
    Gynecol Endocrinol; 2013 Jan 20; 29(1):87-90. PubMed ID: 22835064
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, Yoshida M.
    Anticancer Res; 2001 Jan 20; 21(4B):2925-32. PubMed ID: 11712788
    [Abstract] [Full Text] [Related]

  • 13. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells.
    Tosca L, Ramé C, Chabrolle C, Tesseraud S, Dupont J.
    Reproduction; 2010 Feb 20; 139(2):409-18. PubMed ID: 19906888
    [Abstract] [Full Text] [Related]

  • 14. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.
    J Clin Oncol; 2008 Feb 20; 26(6):897-906. PubMed ID: 18180460
    [Abstract] [Full Text] [Related]

  • 15. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
    Cai D, Sun H, Qi Y, Zhao X, Feng M, Wu X.
    Int J Gynecol Cancer; 2016 Nov 20; 26(9):1667-1672. PubMed ID: 27654259
    [Abstract] [Full Text] [Related]

  • 16. Metformin: taking away the candy for cancer?
    Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG.
    Eur J Cancer; 2010 Sep 20; 46(13):2369-80. PubMed ID: 20656475
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
    Hanawa S, Mitsuhashi A, Shozu M.
    PLoS One; 2018 Sep 20; 13(2):e0192759. PubMed ID: 29444159
    [Abstract] [Full Text] [Related]

  • 18. Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients.
    Carvajal R, Rosas C, Kohan K, Gabler F, Vantman D, Romero C, Vega M.
    Hum Reprod; 2013 Aug 20; 28(8):2235-44. PubMed ID: 23595973
    [Abstract] [Full Text] [Related]

  • 19. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
    Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, Bae-Jump VL.
    Cancer Med; 2015 Feb 20; 4(2):161-73. PubMed ID: 25417601
    [Abstract] [Full Text] [Related]

  • 20. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.
    Anticancer Res; 2012 May 20; 32(5):1627-37. PubMed ID: 22593441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.